The identification of rhesus TRIM5␣ (rhTRIM5␣) as a potent intracellular human immunodeficiency virus (HIV) restriction factor (37) has fueled intensive investigation into how this factor interferes with HIV type 1 (HIV-1) infection. rhTRIM5␣ has also attracted attention as a potential therapeutic for HIV disease (28) . TRIM5␣ proteins belong to the tripartite motif family, and they contain RING, B-box 2, and coiled-coil domains, as well as a C-terminal PRY/SPRY (B30.2) domain (15, 18) . Observations from multiple groups support the notion that rhTRIM5␣ restricts HIV at multiple points of the viral replication cycle (3) . Acting after viral entry but prior to integration, rhTRIM5␣ accelerates cytosolic capsid disassembly (9, 38) and prevents accumulation of reverse transcriptase products (37) . Proteasome inhibitors restore reverse transcript accumulation while still preserving restriction of HIV-1, leading to the proposal that disruption of preintegration complex trafficking to the nucleus is a key component of rhTRIM5␣-mediated restriction of HIV infection (4, 41) . More recently, rhTRIM5␣ overexpression was shown to limit production of infectious virus, but not the infectivity of released virions, in cells previously infected with HIV-1 (32) . However, there is also evidence that this may be an in vitro phenomenon observed with the overexpression of either human TRIM5␣ (huTRIM5␣) or rhTRIM5␣ protein in cell lines (43) . The human counterpart of rhTRIM5␣, huTRIM5␣, can restrict replication of some retroviruses, but it is largely ineffective against HIV-1 (28). But a huTRIM5␣ derivative containing five rhesus monkey amino acid residues in the human PRY/SPRY (B30.2) domain restricts HIV-1 replication nearly as potently as rhTRIM5␣ (39) . In fact, simply replacing a single arginine residue with proline at position 332 in huTRIM5␣ confers significant HIV-1 and simian immunodeficiency virus (SIV) restriction (24) .
HIV-1 can spread between cells by cell-free (released virions) or cell-associated (direct transfer between cells) mechanisms. While cell-free viral transmission is most commonly studied in vitro, there is growing appreciation that cell-associated spread of HIV-1 is an important, if not the primary, mode of HIV-1 spread in vivo (17) . Cell-associated HIV-1 spread is estimated to be several orders of magnitude more efficient than cell-free transmission (13) . This difference is due to multiple factors, such as avoidance of the humoral immune response (27) , as well as concentration of adhesion molecules, viral receptors, and key cellular signaling components at the site of cell contact (19, 35) . Moreover, directional mechanisms such as establishment of filopodial bridges that direct the virus between cells (33) and polarization of the cytoskeleton toward the target cell (18) contribute to the increased efficiency of cell-associated transmission.
The intent of this study was to evaluate the suitability of rhTRIM5␣ for anti-HIV-1 adoptive T-cell therapy (22, 23) . We found that while rhTRIM5␣ could effectively prevent cell-free HIV-1 infection of primary human CD4 T cells, it was unable to prevent HIV infection mediated by cell-to-cell contact between rhTRIM5␣-expressing and HIV-1-infected human CD4 T cells. HIV-1-infected rhTRIM5␣-expressing cells produced infectious virions, but they were unable to spread the infection efficiently to other rhTRIM5␣-expressing cells, even via cell-to-cell contact. Thus, our studies
FIG. 1. Expression of rhTRIM5␣ restricts HIV-1 infection in primary human CD4 T cells. (A)
Schematic diagram of the constructs used in this study. Expression of huTRIM5␣ (gray), rhTRIM5␣ (white), or a modified version of human TRIM5␣ (huTRIM5␣ r323-332 ) (mix of gray and white) was linked to GFP expression via a T2A sequence and a flexible RSGSG linker. In this configuration, two additional residues (ProArg) occupy the TRIM5␣ N terminus. (B) Western blot analysis of TRIM5␣ expression in primary human CD4 T cells transduced with the indicated lentiviral suggest that rhTRIM5␣ may be an effective in vivo antiviral agent only when expressed by the majority of cells.
MATERIALS AND METHODS
Lentiviral vector construction and production. Replication-defective lentiviral vectors were generated and concentrated, and their titers were determined, as previously described (30) . TRIM5␣-expressing lentiviral vectors were constructed by inserting cDNAs encoding huTRIM5␣, rhTRIM5␣, or huTRIM5␣ r323-332 (39) into the lentiviral expression vector pELNS. pELNS was derived from pRRL-SIN-CMVeGFP-WPRE (14) by replacing the internal cytomegalovirus promoter with the EF-1␣ promoter. A green fluorescent protein (GFP) cassette and an 18-amino-acid T2A motif cassette including a flexible linker (40) were inserted upstream of the TRIM5␣ coding sequence, permitting bicistronic expression of GFP and TRIM5␣. pCLPS mCD28 167* was constructed by inserting a stop codon into pCLPS mCD28-h28 after residue 167, eliminating the CD28 cytoplasmic tail signaling domains (30) . The monomeric red fluorescent protein (RFP) (6)-encoding vector VRX1031, in which RFP expression is driven by the HIV-1 NL4-3 viral long terminal repeat, was produced using a protocol designed for clinical-grade lentiviral vector production (25) .
Western blot analysis. Cytoplasmic protein lysates were made as previously described (35) , using 1% Nonidet P-40 lysis buffer and a complete cocktail of protease inhibitors (Roche, Indianapolis, IN); 250,000 cell equivalents/lane were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore, Bedford, MA). Blots were incubated with either a 1:1,000 dilution of anti-huTRIM5␣ rabbit polyclonal antibody CT (Imgenex, San Diego, CA) or a 1:1,000 dilution of anti-AKT rabbit polyclonal antibody (Cell Signaling Technology, Danvers, MA), followed by incubation with a 1:1,000 dilution of goat anti-rabbit-horseradish peroxidase (Cell Signaling Technology). Proteins were visualized using ECL (GE Healthcare, Piscataway, NJ) and analyzed on a Gel-Doc densitometer (Bio-Rad, Hercules, CA).
Cell isolation, culture, and transduction. Peripheral blood mononuclear cells (PBMCs) were obtained by leukapheresis of healthy volunteer donors by the University of Pennsylvania Human Immunology Core. All specimens were collected under a University Institutional Review Board-approved protocol, and informed consent was obtained from each donor. Primary human CD4 T cells were purified by negative selection as previously described (10) , and residual red blood cells were removed by ACK lysis (BioWhittaker, Walkersville, MD). Purified human CD4 T cells were transduced by adding 250 to 350 l of concentrated lentiviral vector (approximately 5 ϫ 10 7 transducing units) to 250,000 anti-CD3/CD28 bead-activated cells plated at 1 ϫ 10 6 /ml (250 l) in a 48-well plate. Antibody-coated beads were removed after 5 days of culture. Expression of introduced huTRIM5␣, rhTRIM5␣, or huTRIM5␣ r323-332 was monitored using the GFP signal from the bicistronic GFP-2A-TRIM5␣ transcript.
Rhesus CD4 T cells were purified from PBMCs 4 days after stimulation with concanavalin A (ConA) (1 g/ml) (Sigma-Aldrich, St. Louis, MO) and interleukin-2 (IL-2) (300 IU/ml). Activated rhesus CD4 T cells were isolated by negative selection using StemSep rhesus monkey CD4 ϩ T-cell enrichment cocktail and human EasySep magnetic nanoparticles (both from StemCell Technologies, Vancouver, Canada). Rhesus and human CD4 T cells were distinguished by staining with species-specific fluorescein isothiocyanate-conjugated anti-CD3 antibodies (human-specific OKT3 [eBioscience] or rhesus-specific FN-18 [Biosource, Camarillo, CA]) combined with allophycocyanin-conjugated pan-reactive anti-CD4 antibody L200 (BD Pharmingen, San Diego, CA). GHOST-CCR5 cells (8) were maintained in selective media as previously described (26) .
HIV-1 infections. HIV-1 SF162 and HIV-1 BK132 viral stocks were prepared by harvesting supernatant from infected phytohemagglutinin/IL-2-stimulated human PBMC cultures. Anti-CD3/CD28 bead-stimulated human CD4 T cells were challenged with cell-free HIV-1 on a p24-normalized basis (50 ng p24/0.5 ϫ 10 6 cells) at 48 h after bead removal, i.e., 7 days poststimulation. Zidovudine (AZT) (NIH AIDS Research and Reference Reagent Program, Germantown, MD) was added where indicated to a final concentration of 10 g/ml. Transwell assays were performed using 12-well or 24-well 0.4-m polyester-membrane dishes (Corning Life Sciences, Corning, NY). Cell-free HIV was added to both wells for HIV challenge. Cell-associated HIV-1 infections used untransduced human CD4 T cells infected with cell-free HIV-1 SF162 3 days previously as donor cells; target cells were uninfected human or rhesus CD4 T cells.
HIV detection. HIV-1 infection was monitored by intracellular HIV-1 Gag staining using the Caltag Fix and Perm kit (Invitrogen, Carlsbad, CA) and the KC57 anti-Gag-RD1 antibody (Coulter, Hialeah, FL), following the manufacturers' instructions. Cell populations were acquired using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA) and analyzed using Flowjo software (Tree Star, Ashland, OR). p24 core antigen concentrations in culture supernatants were measured by p24 enzyme-linked immunosorbent assay (NEN-Perkin Elmer Life Sciences, Boston, MA). Enzyme-linked immunosorbent assays were performed by the University of Pennsylvania Center for AIDS Research (Penn-CFAR) (http://www.uphs.upenn .edu/aids/). The relative infectivity of culture supernatants was measured by infection of GHOST-CCR5 cells. Dilutions of culture supernatant were added to GHOST-CCR5 cells, and 48 h later, cultures were analyzed for GFP and Gag expression by fluorescence-activated cell sorter (FACS) analysis. Copies of HIV gag DNA were measured by real-time PCR and normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene, using reagents and conditions standardized by Penn-CFAR. Standard curves were constructed using the HIV-1-infected ACH-2 cell line (11) . The primers used were gag-6F (5Ј-CATGTTTTCAGCATTATCAG AAGGA-3Ј) and gag-84R (5Ј-TGCTTGATGTCCCCCCACT-3Ј). The sequence of the probe was (6-carboxyfluorescein)-5Ј-CCACCCCACAAGATTTAAACACCAT GCTAA-3Ј-(Black Hole Quencher 1).
Sorting and characterization of HIV-1-infected TRIM5␣-expressing human CD4 T cells. Viable human CD4 T cells transduced with rhTRIM5␣, huTRIM5␣ rh323-332 , or huTRIM5␣ were sorted as GFP-positive (GFP Sorted human CD4 T cells were washed and resuspended in complete RPMI supplemented with 300 U/ml IL-2, counted, plated at 1 ϫ 10 6 cells/ml, and restimulated with anti-CD3/CD28 antibody-coated beads. On various days after restimulation, supernatants and cell pellets were collected. In some experiments, on day 6 after restimulation, sorted (donor) cells were mixed at a 1:1 ratio with similarly activated TRIM5␣-expressing or untransduced (recipient) CD4 T cells. Donor and recipient populations were distinguished by using cells with different HLA A*02 status. HLA A*02 staining was performed using anti-A2 biotin-conjugated primary antibody (One Lambda, Canoga Park, CA) and streptavidin-allophycocyanin as the secondary antibody (BD Pharmingen, San Diego, CA). 24, 37, 42). To determine whether rhTRIM5␣ could restrict replication-competent HIV-1 in primary human CD4 T cells, we constructed lentiviral vectors that coexpressed GFP and either huTRIM5␣, rhTRIM5␣, or a modified huTRIM5␣ (huTRIM5␣ r323-332 ) via a T2A sequence that induces a ribosomal skipping mechanism and results in the production of two proteins from a single transcript (Fig. 1A ) (39) . The latter construct is a huTRIM5␣ derivative in which five amino acids in the PRY/SPRY (B30.2) domain were replaced with their corresponding residues from the rhTRIM5␣ protein (39) . We included huTRIM5␣ r323-332 -expressing constructs in our analyses because of its reported potency (39) and the probability that it may be less immunogenic than wild-type rhTRIM5␣ as a human therapeutic. Purified human CD4 T cells were stimulated with anti-CD3/ CD28-coated beads, transduced with TRIM5␣-expressing lentiviral vectors, and expanded using conditions that permit CCR5 reexpression (7, 12) . TRIM5␣ expression was examined at 6 days posttransduction by Western blotting and densitometry (Fig. 1B) , using a polyclonal antiserum that recognizes both huTRIM5␣ and rhTRIM5␣. We observed at least threefold overexpression of TRIM5␣ in transduced cells compared to untransduced cells or cells transduced with the control vector mCD28 167*. Before challenging human CD4 T cells with replication-competent HIV-1, we first determined whether introduced TRIM5␣ could protect primary human CD4 T cells from challenge with a replication-defective lentiviral vector. We observed efficient restriction of challenge with cell-free preparations of the RFP-encoding lentiviral vector VRX1031 in both rhTRIM5␣-and huTRIM5␣ r323-332 -expressing human CD4 T cells, with rhTRIM5␣ expression conferring the more potent resistance. In contrast, only modest restriction of the incoming RFP vector was seen in huTRIM5␣-overexpressing human CD4 T cells (Fig. 1C) . These data indicate that rhTRIM5␣ and huTRIM5␣ r323-332 can protect primary human CD4 T cells in a single-round challenge assay and are consistent with previously published observations (39) .
RESULTS

Expression of rhTRIM5␣ restricts HIV-1 infection in pri-
We next performed challenge experiments with either cellfree HIV-1 SF162 (an R5 strain) or the primary, highly cytopathic X4 isolate HIV-1 BK132 . Expression of rhTRIM5␣ in primary human CD4 T cells efficiently restricted both HIV-1 SF162 and HIV-1 BK132 cell-free viral challenge (Fig. 1D) . Resistance to infection was robust: ϳ40% of untransduced CD4 T cells became HIV-1 SF162 infected, whereas HIV Gag expression remained at background levels in rhTRIM5␣-expressing cells. CD4 T cells expressing huTRIM5␣ r323-332 were less susceptible to HIV-1 SF162 infection, but they were not completely protected. huTRIM5␣ r323-332 -expressing cells displayed only slight resistance to HIV-1 BK132 infection, indicating that the huTRIM5␣ r323-332 antiviral effect is less potent than that of rhTRIM5␣. In contrast, overexpression of huTRIM5␣ had little effect against either virus compared to untransduced cells. These data indicate that rhTRIM5␣ is a potent HIV-1 restriction factor when expressed in primary human CD4 T cells; furthermore, because huTRIM5␣ r323-332 was unable to completely recapitulate the effects of rhTRIM5␣, our results imply that additional residues and regions within the rhTRIM5␣ PRY/SPRY (B30.2) domain contribute to the potency of HIV-1 restriction.
Human rhTRIM5␣-expressing CD4 T cells are not protected from HIV-1 infection when cocultured with unmodified, HIV-1-infected human CD4 T cells. To model an adoptive T-cell therapy scenario in which ex vivo expanded, modified CD4 T cells are infused into an environment of infected, unmodified CD4 T cells, we mixed equal numbers of TRIM5␣-expressing cells and untransduced CD4 T cells and then performed cell-free HIV challenge to determine if rhTRIM5␣-expressing cells were preferentially protected from HIV-1 infection. Surprisingly, we did not observe preferential protection of rhTRIM5␣-or huTRIM5␣ r323-332 -expressing CD4 T cells, as cocultured TRIM5␣-expressing and untransduced cells contained similar levels of intracellular HIV-1 Gag ( Fig.  2A) . Moreover, we predicted that rhTRIM5␣-expressing cells would be preferentially expanded in HIV-1-infected cultures, since they would be less sensitive to HIV-1 cytopathic effects. However, we observed minimal if any preferential expansion, as the ratio of rhTRIM5␣-expressing cells to untransduced cells remained essentially unchanged throughout the experiment. To rule out that these findings were unique to HIV-1 SF162 and HIV-1 BK132 , we performed identical experiments challenging the mixed T-cell cultures with HIV-1 Ba-L and HIV-1 US-1 and obtained similar results (data not shown).
To exclude the possibility that TRIM5␣-expressing cells were simply taking up soluble HIV-1 Gag as a result of coculture with HIV-1-infected cells and thus staining positive for intracellular p24 without actually being infected, we pretreated TRIM5␣-expressing cells with 10 M AZT for 15 min prior to the addition of washed, robustly HIV-1 SF162 -infected (day 3 postinfection), untransduced CD4 T cells from the same donor ( the presence of AZT, even when cocultured with productively infected cells, suggested that the ability to observe Gag staining ( Fig. 2A) resulted from infection of TRIM5␣-expressing cells rather than from uptake of released virions. These data indicate that rhTRIM5␣ antiviral activity is compromised in the presence of untransduced, HIV-1-infected CD4 T cells. In contrast, in single-round lentiviral challenge assays of mixed cocultures using a high-titer replication-defective vesicular stomatitis virus G protein (VSV-G)-pseudotyped RFP-encoding lentiviral vector, potent restriction was observed in rhTRIM5␣-and huTRIM5␣ r323-332 -expresssing cells (Fig. 2C) ; modest restriction was observed in huTRIM5␣-overexpressing CD4 T cells despite coculture with untransduced CD4 T cells, comparable to that seen in uniform cultures (Fig. 1C) . Clearly, in contrast to the results obtained with replication-competent HIV-1, coculture with untransduced human CD4 T cells did not compromise the ability of rhTRIM5␣-expressing CD4 T cells to restrict incoming lentiviral vectors in single-round assays.
Cell-to-cell contact with HIV-infected, untransduced CD4 T cells is required to circumvent rhTRIM5␣-mediated restriction of HIV-1 in human CD4 T cells. We considered two possibilities to explain how rhTRIM5␣ robustly protected pure populations of rhTRIM5␣-expressing cells from HIV-1 infection yet failed to protect populations of rhTRIM5␣-expressing cells when they were combined with untransduced CD4 T cells: (i) the untransduced, HIV-1-infected T cells continually produced cell-free HIV-1, which saturated the rhTRIM5␣ antiviral effect (37), or (ii) cell-associated HIV-1 transmission circumvents rhTRIM5␣-mediated restriction. To distinguish between these two possibilities, we physically separated TRIM5␣-expressing cells and untransduced CD4 T cells using a transwell apparatus, permitting HIV-1, but not cells, to pass from one chamber to the other. Both orientations of TRIM5␣-expressing and untransduced CD4 cells within the transwell apparatus were examined (Fig. 3A) . Cell-free HIV-1 was added to both chambers, and HIV-1 infection was monitored by intracellular HIV-1 Gag staining as before. Expression of rhTRIM5␣ in human CD4 T cells completely restricted cellfree HIV infection, despite the presence of robustly infected untransduced cells in the opposite transwell chamber, which resulted in continual cell-free viral challenge as well as exposure to soluble p24 (Fig. 3B) . Expression of huTRIM5␣ r323-332 provided modest protection from HIV-1 SF162 infection but little or no protection from HIV-1 BK132 infection. Overexpression of huTRIM5␣ did not provide protection from either strain of HIV-1. In fact, slightly higher levels of HIV-1 Gag staining were seen in untransduced cells cocultured with huTRIM5␣-expressing cells than in untransduced CD4 T cells cultured alone. Similar results were obtained when we switched the orientation of TRIM5␣-expressing and untransduced cells (Fig. 3C) , indicating that minor density-dependent effects on the spread of HIV-1 infection observed with cells cultured in the smaller upper chamber did not affect our findings. Together, these data suggest that cell-to-cell contact with HIV-1-infected untransduced CD4 T cells overcomes the rhTRIM5␣ antiviral effect, which potently inhibits infection with cell-free HIV-1.
Rhesus macaque CD4 T cells can be infected with HIV-1 via cell-to-cell contact with preinfected human CD4 T cells. Rhesus macaque CD4 T cells are highly resistant to cell-free HIV-1 infection (5, 34). We also were unable to infect primary rhesus CD4 T cells with cell-free HIV-1 SF162 under conditions that produced a spreading infection in primary human CD4 T cells (Fig. 4A) . Similarly, primary rhesus CD4 T cells were also not infected with HIV-1 despite continual cell-free HIV-1 SF162 challenge via coculture across a 0.4-m transwell from preinfected human CD4 T cells, whereas initially uninfected human CD4 T cells became infected under these conditions (Fig. 4B) .
The observation that cell-to-cell contact facilitated escape from rhTRIM5␣-mediated restriction in human CD4 T cells raised the question of whether rhesus CD4 T cells could become infected by cell-to-cell contact with HIV-infected human CD4 T cells. To address this possibility, we mixed HIV-1 SF162 -infected human CD4 T cells with ConA-and IL-2-stimulated rhesus CD4 T cells. HIV-1 infection was then monitored every 3 days by intracellular HIV-1 Gag staining, with rhesus and human CD4 T-cell populations distinguished based on staining with rhesus-specific anti-CD3 antibody (FN-18), combined with the pan-reactive anti-CD4 monoclonal antibody L200. To our surprise, rhesus CD4 T cells were infected with HIV-1 after 3 days of coculture with HIV-1-infected human CD4 T cells (Fig. 4C) . The disparity in outcomes between this coculture experiment and the Transwell experiment (Fig. 4B) indicates that cell-to-cell contact with preinfected human CD4 T cells and, presumably therefore, cell-associated HIV-1 transmission are sufficient to infect rhesus CD4 T cells with HIV-1. We also examined the ability of AZT to block cell-associated HIV-1 transmission to cocultured rhesus CD4 T cells (Fig. 4C) . HIV-1 SF162 -preinfected human CD4 T cells were washed and then mixed with primary rhesus CD4 T cells that had been pretreated with 10 M AZT for 15 min. The cells were cocultured in the presence of AZT for an additional 3 days. The ability to detect HIV-infected rhesus CD4 T cells was greatly reduced in the presence of AZT, indicating that AZT was able to block the further spread of HIV-1 infection from the preinfected human CD4 T cells and suggesting that the Gag positivity observed in the absence of AZT treatment represented actual HIV-1 infection of rhesus CD4 T cells.
HIV-infected human CD4 T cells cannot establish a sustained infection in cocultured rhesus CD4 T cells.
There has been considerable interest in using rhesus macaques as a model of HIV pathogenesis (21) . However, because rhesus macaques are resistant to HIV-1 infection, SIV or SHIV strains have been employed almost exclusively in these studies, limiting the evaluation of agents that specifically target HIV-1 pathogenesis. Since rhesus CD4 T cells are susceptible to cellto-cell transmission of HIV-1, we wanted to determine whether a sustainable, spreading infection of rhesus CD4 T cells ensued when a small number of HIV-1-infected human cells were mixed with rhesus CD4 T cells and allowed to expand for longer periods of time (Fig. 5) . As the cultures expanded, the human CD4 T cells were diluted out, presumably due to the cytopathic effects of HIV-1. Notably, we were unable to observe a spreading HIV-1 infection among the rhesus CD4 T cells, suggesting that adoptive transfer of HIV-1-infected human CD4 T cells to rhesus monkeys would not lead to a productive infection. Thus, HIV-1 infection could be established via cell-to-cell transfer in cultures containing human and rhesus CD4 T cells but could not be propagated further among the rhesus CD4 T-cell population.
HIV-1-infected rhTRIM5␣-expressing cells produce infectious HIV. Our inability to establish a spreading HIV-1 infection within rhesus CD4 T cells suggested that cell-to-cell transmission of HIV-1 between infected and uninfected rhesus CD4 T cells was blocked. In addition to restricting infection by HIV-1, it has been reported that rhTRIM5␣, when expressed in an HIV-1-infected cell, blocks the production but not the infectivity of released virions (32) , but this is controversial (43) . Therefore, we measured the ability of HIV-infected, rhTRIM5␣-expressing human CD4 T cells to produce infectious virions (Fig. 6) . rhTRIM5␣-expressing human CD4 T cells were cocultured with untransduced human CD4 T cells and challenged with cell-free HIV-1 SF162 . Twelve days later, rhTRIM5␣-expressing cells were collected by viable cell sorting. The sorted cells were restimulated with anti-CD3/CD28-coated beads and cultured for an additional 12 days. At early time points, the restimulated cultures contained many HIV Gag-positive cells, but by day 9, intracellular Gag was virtually undetectable (Fig. 6A) . This is consistent with the observed inability of HIV-1 to establish a spreading infection in primary rhesus CD4 T cells (Fig. 5) . At various time points after restimulation, cell pellets were analyzed for HIV-1 gag DNA by PCR (Fig. 6B) . The cultures were strongly gag positive until day 9, but the gag copy number declined by approximately 10-fold by day 12, reinforcing the notion that HIV-1 is unable to establish a spreading infection in rhTRIM5␣-expressing cells. Interestingly, we did observe that after 9 days of culture, intracellular p24 staining was reduced whereas HIV-1 gag DNA levels remained constant. This likely reflects the stability of HIV-1 gag DNA in this culture system. We also tried to culture huTRIM5␣-expressing cells side by side with the rhTRIM5␣-expressing cells. Unfortunately, these cultures died after 5 days due to cytopathic effects of the virus (data not shown). Next, we measured the ability of the HIV-1-infected, rhTRIM5␣-expressing human CD4 T cells to produce infectious virions. Using culture supernatants harvested at 2 days after restimulation, we compared the infectivity of virions produced by HIV-infected rhTRIM5␣-expressing CD4 T cells with the infectivity of a conventional HIV-1 SF162 viral stock using CCR5-expressing GHOST cells (Fig. 6C) . When normalized for p24 input, virus produced by rhTRIM5␣-expressing human CD4 T cells was at least as infectious as a conventional viral stock. These data indicate that (i) rhTRIM5␣-expressing CD4 T cells can be infected with HIV-1 and (ii) the infected cells produce infectious virions.
The ability of HIV-1-infected rhTRIM5␣-expressing human CD4 T cells to induce a spreading infection depends on the TRIM5␣ status of the target cell. Our inability to establish a spreading HIV-1 infection within rhesus CD4 T cells suggested that cell-to-cell transmission of HIV-1 between infected and uninfected rhesus CD4 T cells was blocked. Our previous data (Fig. 4) indicating that rhTRIM5␣ can restrict cell-free but not cell-associated HIV-1 transmission were obtained using untransduced HIV-infected donor CD4 T cells. We next asked whether rhTRIM5␣ expression could prevent cell-associated HIV-1 spread if expressed in both donor and recipient cells (Fig. 7) . Because rhesus CD4 T cells contain other restriction factors such as APOBEC3G (16), we used primary human CD4 T cells transduced with rhTRIM5␣ to examine the restrictive function of rhTRIM5␣ in isolation. We first purified HLA-A*02-negative, HIV-infected, rhTRIM5␣-expressing human CD4 T cells, as described for Fig. 6 . These cells were cultured with uninfected TRIM5␣-expressing or untransduced CD4 T cells from an HLA-A*02 positive donor. Cocultures were then evaluated for the presence of a spreading HIV-1 infection, using cell surface HLA-A*02 expression to gate donor (HLA-A*02-negative) and recipient (HLA-A*02-positive) populations. At day 4 postmixing, we observed that sorted, HIV-1-infected rhTRIM5␣-expressing human CD4 T cells could productively infect untransduced and huTRIM5␣-overexpressing human CD4 T cells, and a spreading infection ensued in both recipient and donor populations (Fig. 7A) . By day 8 postmixing, it was apparent that expression of huTRIM5␣ r323-332 in the recipient cell delayed but did not eliminate HIV-1 infection induced by coculture with sorted rhTRIM5␣-expressing donor cells, as well as the spread of the infection between both donor and recipient populations. In contrast, there was little evidence of HIV-1 infection of fresh recipient rhTRIM5␣-expressing cells cocultured with sorted rhTRIM5␣-expressing donor cells at days 4 and 8 postmixing, and a spreading infection did not ensue in either HLA-A*02-positive recipient or HLA-A*02-negative donor populations; HIV-1 infection appeared to have been effectively contained (Fig. 7B) . Together, these data suggest that rhTRIM5␣ expression in both donor and recipient human CD4 T cells can effectively block cell-associated transmission of HIV-1 and prevent the spread of HIV-1 infection.
DISCUSSION
rhTRIM5␣ is a potent HIV-1 restriction factor, and as such, it has generated considerable attention as a potential anti-HIV therapeutic. The studies presented here reveal that while rhTRIM5␣ efficiently blocks infection by cell-free HIV-1 ( Fig.  1) , it is considerably less effective at preventing cell-associated HIV-1 transfer. As shown in Fig. 2 and 3 , when rhTRIM5␣ is expressed only in target cells, it is unable to block infection by cell-associated HIV-1. Furthermore, primary rhesus CD4 cells can also be infected by coculture with HIV-1-infected human CD4 cells (Fig. 4) . However, rhTRIM5␣ is able to block HIV transmission by either cell-free or cell-associated mechanisms when it is expressed in both donor and recipient cells (Fig. 5,  6 , and 7), explaining why spreading infections do not ensue when a small amount of infected human cells is mixed with rhesus CD4 cells. Thus, our studies indicate that rhTRIM5␣ is the first cell-intrinsic antiviral mechanism of which we are aware that can block one form of cell entry (cell free) but not another (cell associated).
While HIV-1 can be transmitted via cell-free or cell-associated mechanisms, robust HIV-1 infection requires cell-to-cell spread, at least in vitro (36) . Cell-free HIV-1 can be restricted very efficiently by rhTRIM5␣ (37), although it is saturable. It is conceivable that the inability of rhTRIM5␣ to restrict cellassociated HIV-1 transmission is solely a consequence of saturating rhTRIM5␣'s functional capacity, perhaps due to locally high virion concentration at the site of cell contact. However, other factors could contribute to the differential ability of rhTRIM5␣ to restrict cell-free versus cell-associated infection. Since the virological synapse shares many features with the immunological synapse (31), it is likely that significant sections of the membrane of the donor cell are transferred with HIV-1 to the recipient cell during cell-to-cell transfer (33) . This membrane component may form a shield that protects the incoming virus from rhTRIM5␣ restriction and thus allows infection of rhTRIM5␣-expressing cells.
Furthermore, we also established that TRIM5␣-mediated restriction of cell-to-cell HIV-1 transmission requires rhTRIM5␣ expression in both donor and recipient cells. Sakuma et al. observed that rhTRIM5␣ overexpression reduces virion production by infected cells (32) , and we observed less p24 HIV-1 GAG expression in HIV-1-infected rhTRIM5␣-expressing cells (data not shown). However, we also observed that virions produced by HIV-1-infected rhTRIM5␣-express- ing cells, on a p24-normalized basis, were at least as infectious as viral stocks prepared in human PBMCs (Fig. 6) . Therefore, the presence of rhTRIM5␣ in the donor cell would presumably reduce the number of virions available for cell-to-cell transmission, perhaps below the threshold required to saturate the rhTRIM5␣ present in the recipient cell. This is one scenario that could explain how transmission of HIV-1 from an infected rhTRIM5␣ donor cell to an rhTRIM5␣-expressing recipient cell is blocked. Another possible explanation is that the presence of huTRIM5␣ or rhTRIM5␣ in the producer cell influences or augments the activity of TRIM5␣ restriction in the recipient cell. It is known that rhTRIM5␣ becomes incorporated into virions (32) , and this amount of virion-associated rhTRIM5␣ may be sufficient to block cell-to-cell infection of rhTRIM5␣-expressing but not huTRIM5␣-expressing cells. In other words, the additional virion-associated rhTRIM5␣ transferred may tip the balance so that rhTRIM5␣-expressing cells can block cell-to-cell transmission of HIV-1 infection. Our data, when combined with these previous observations, suggest but do not prove that factors other than virion concentration may contribute to the differential ability of rhTRIM5␣ to restrict cell-free and cell-associated infections. In fact, these postulated mechanisms are not mutually exclusive, and indeed they may work in unison to negate the effects of rhTRIM5␣ during cell-to-cell transmission.
The data presented here provide some insight into the circumstances in which rhTRIM5␣ may be a useful in vivo anti-HIV therapeutic. Given the fact that only a small fraction of the total T-cell compartment can be reconstituted using current adoptive T-cell therapy guidelines (20, 23) , we would predict that rhTRIM5␣-expressing cells would not be preferentially protected from HIV-1 infection, since cell-associated transmission plays a pivotal role in transmitting HIV in vivo (17) . There is even less optimism for this approach when one considers that cells expressing rhTRIM5␣ may be immunogenic and thus one would be forced to use a less effective version such as huTRIM5␣ r323-332 . Our studies show that while huTRIM5␣ r323-332 expression has antiviral effects, it is clearly not as potent as rhTRIM5␣. This finding was not unexpected, as other studies have shown that variable regions within the PRY/SPRY (B30.2) domain beside V1 were required for full antiviral activity (24, 29) . However, there is still room for optimism regarding the use of rhTRIM5␣ expression in immune reconstitution. Stem cell therapy (1, 2) or future T-cell adoptive therapy approaches that could repopulate the vast majority of T cells with rhTRIM5␣ activity would likely be very effective at controlling and possibly eliminating HIV-1 infection, since these cells would be protected from both cell-free and cell-associated HIV-1 infection.
